Literature DB >> 1280247

Murine ascitic fluids contain varying amounts of an inhibitor that interferes with complement-mediated effector functions of monoclonal antibodies.

B J Appelmelk1, A M Verweij-Van Vught, J J Maaskant, L G Thijs, D M MacLaren.   

Abstract

The ability of murine monoclonal antibodies (mAbs), directed to the inner core of Gram-negative bacterial lipopolysaccharide (LPS, endotoxin), to enhance complement-mediated killing of bacteria, was investigated. The mAbs were tested as present in ascitic fluid. It was found that ascites contains an factor that inhibited the activity of complement. This effect was evident in assays for complement-mediated lysis of antibody-coated Gram-negative bacteria (bacterial killing) or of opsonised red blood cells. Moreover, the amount of inhibitor was found to vary from one ascites to another and spanned a 60-fold range. Thus, in vitro or in vivo experiments where complement is known to play a determining role may yield incorrect results when ascites is used as a source of antibody; the use of ascites prepared from irrelevant antibody as a negative control does not eliminate this problem.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280247     DOI: 10.1016/0165-2478(92)90037-o

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  A lytic monoclonal antibody to Trypanosoma cruzi bloodstream trypomastigotes which recognizes an epitope expressed in tissues affected in Chagas' disease.

Authors:  N W Zwirner; E L Malchiodi; M G Chiaramonte; C A Fossati
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

2.  Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection.

Authors:  Michael E Woodman; Anne E Cooley; Jennifer C Miller; John J Lazarus; Kathryn Tucker; Tomasz Bykowski; Marina Botto; Jens Hellwage; R Mark Wooten; Brian Stevenson
Journal:  Infect Immun       Date:  2007-04-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.